Quantisnow Logo
Dashboard

Director Gikakis Nicolas covered exercise/tax liability with 3,289 shares, decreasing direct ownership by 8% to 38,041 units (SEC Form 4)

$AEMD
Medical/Dental Instruments
Health Care
Get the next $AEMD alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Get startedLearn more

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

Get startedLearn more
App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $AEMD alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AEMD

DatePrice TargetRatingAnalyst
6/25/2021$5.00 → $9.00Buy
HC Wainwright & Co.
More analyst ratings

$AEMD
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Presenting on the Emerging Growth Conference 80 Day 2 on March 27 Register Now

    MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 - TodayMarch 26, 2025 11:00Virtual Lobby opens.Register for the Conference.  If you already registered, go back to

    $AEMD
    $ASPI
    $ATCH
    $BNRG
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

  • Presenting on the Emerging Growth Conference 80, Day 1 on March 26 - Register Now

    MIAMI, March 25, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com, a leading independent small cap media portal, announces the schedule of the 80th Emerging Growth Conference on March 26 & 27, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com. For updates, follow us on Twitter. Day 1March 26, 2025 11:00Virtual Lobby opens.Register for the Conference. If you already registered, go

    $AEMD
    $ASPI
    $ATCH
    $BNRG
    Medical/Dental Instruments
    Health Care
    Major Chemicals
    Industrials

  • Aethlon Medical Publishes Preclinical Data on the Hemopurifier® in Transplant Immunology Journal

    Preclinical Data Suggests Expanded Therapeutic Potential of the Hemopurifier® Beyond Virology and Oncology Results Support Further Evaluation of the Hemopurifier® as Part of a Machine Perfusion Circuit to Further Assess its Impact on the Function of Retrieved Kidneys SAN DIEGO, March 10, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases and for use in organ transplantation, today announced the publication of a pre-clinical study in the peer-reviewed journal Transplant Immunology (https://doi.org/10.1016/j.trim.2025.102215) on February 28, 2025, entitled, " A lectin a

    $AEMD
    Medical/Dental Instruments
    Health Care

$AEMD
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$AEMD
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$AEMD
 SEC Filings

See more

$AEMD
 Financials

Live finance-specific insights

See more

  • Aethlon Medical Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update

    Key Milestone Achieved: First Patient treated in Hemopurifier® Safety, Feasibility, and Dose Finding Study for Solid Tumors Not Responding to Anti-PD-1 Antibodies Patient Enrollment Open at Two Australian for Hemopurifier® Cancer Trial Operating Expenses Significantly Reduced Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Feb. 12, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments. Company Updates During the third quarter, a

    $AEMD
    Medical/Dental Instruments
    Health Care

  • Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025

    SAN DIEGO, Feb. 5, 2025 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2024, at 4:15 p.m. ET on Wednesday, February 12, 2025. Management will host a conference call on Wednesday, February 12, 2024, at 4:30 p.m. ET to review financial results and recent corporate developments. Following management's formal remarks, there will be a question and answer session. Interested parties can register for the conference call by navigating to https://dpregister.com/sreg/10196811/fe

    $AEMD
    Medical/Dental Instruments
    Health Care

  • Aethlon Medical Announces Financial Results for the Fiscal Second Quarter Ended September 30, 2024 and Provides Corporate Update

    Achieves Key Milestone with Enrollment of First Two Patients in the Safety, Feasibility, and Dose Finding Study of Aethlon's Hemopurifier® in Patients with Solid Tumors Not Responding to Anti-PD-1 Antibodies Two Australian Sites Open For Patient Enrollment in Hemopurifier® Cancer Trial Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO, Nov. 13, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (NASDAQ:AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2024 and provided an update on recent developments. Company Updates During the seco

    $AEMD
    Medical/Dental Instruments
    Health Care

$AEMD
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more